Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Induction of paracrine signaling in metastatic melanoma cells by PPARγ agonist rosiglitazone activates stromal cells and enhances tumor growth.

Pich C, Meylan P, Mastelic-Gavillet B, Nguyen NT, Loyon R, Trang BK, Moser H, Moret C, Goepfert C, Hafner J, Levesque MP, Romero P, Jandus C, Michalik L.

Cancer Res. 2018 Sep 5. pii: canres.0912.2018. doi: 10.1158/0008-5472.CAN-18-0912. [Epub ahead of print]

PMID:
30185551
2.

Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread.

Ma Q, Dieterich LC, Ikenberg K, Bachmann SB, Mangana J, Proulx ST, Amann VC, Levesque MP, Dummer R, Baluk P, McDonald DM, Detmar M.

Sci Adv. 2018 Aug 8;4(8):eaat4758. doi: 10.1126/sciadv.aat4758. eCollection 2018 Aug.

3.

EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.

Zingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, Santoro R, Levesque MP, Sommer L.

Cancer Cell. 2018 Jul 9;34(1):69-84.e14. doi: 10.1016/j.ccell.2018.06.001. Epub 2018 Jun 28.

PMID:
30008323
4.

Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.

Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B.

Nat Med. 2018 Jul 2. doi: 10.1038/s41591-018-0094-7. [Epub ahead of print]

PMID:
29967347
5.

Melanoma Immunotherapy: Next-Generation Biomarkers.

Hogan SA, Levesque MP, Cheng PF.

Front Oncol. 2018 May 29;8:178. doi: 10.3389/fonc.2018.00178. eCollection 2018. Review.

6.

VLA-4 mediated adhesion of melanoma cells on the blood-brain barrier is the critical cue for melanoma cell intercalation and barrier disruption.

García-Martín AB, Zwicky P, Gruber T, Matti C, Moalli F, Stein JV, Francisco D, Enzmann G, Levesque MP, Hewer E, Lyck R.

J Cereb Blood Flow Metab. 2018 May 15:271678X18775887. doi: 10.1177/0271678X18775887. [Epub ahead of print]

PMID:
29762071
7.

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells.

Sinnberg T, Niessner H, Levesque MP, Dettweiler C, Garbe C, Busch C.

Biol Open. 2018 Jun 7;7(6). pii: bio032656. doi: 10.1242/bio.032656.

8.

Methadone-Not a magic bullet in melanoma therapy.

Brüggen MC, Mangana J, Irmisch A, French LE, Levesque MP, Cheng PF, Dummer R.

Exp Dermatol. 2018 Jun;27(6):694-696. doi: 10.1111/exd.13543.

PMID:
29577418
9.

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.

Zila N, Bileck A, Muqaku B, Janker L, Eichhoff OM, Cheng PF, Dummer R, Levesque MP, Gerner C, Paulitschke V.

Clin Proteomics. 2018 Mar 9;15:13. doi: 10.1186/s12014-018-9189-x. eCollection 2018.

10.

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1.

PMID:
29496664
11.

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.

Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C.

Mol Cancer. 2018 Feb 17;17(1):59. doi: 10.1186/s12943-018-0773-5.

12.

Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma.

Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R, Sommer L.

Nat Commun. 2018 Jan 22;9(1):314. doi: 10.1038/s41467-018-02850-8.

13.

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.

Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B.

Nat Med. 2018 Feb;24(2):144-153. doi: 10.1038/nm.4466. Epub 2018 Jan 8. Erratum in: Nat Med. 2018 Jul 2;:.

PMID:
29309059
14.

Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.

Siliņa K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng P, Curioni-Fontecedro A, Foukas P, Levesque MP, Moch H, Linē A, van den Broek M.

Cancer Res. 2018 Mar 1;78(5):1308-1320. doi: 10.1158/0008-5472.CAN-17-1987. Epub 2017 Dec 26.

PMID:
29279354
15.

Bioinformatics for precision oncology.

Singer J, Irmisch A, Ruscheweyh HJ, Singer F, Toussaint NC, Levesque MP, Stekhoven DJ, Beerenwinkel N.

Brief Bioinform. 2017 Dec 18. doi: 10.1093/bib/bbx143. [Epub ahead of print]

PMID:
29272324
16.

low neurotrophin receptor CD271 regulates phenotype switching in melanoma.

Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R, Sommer L.

Nat Commun. 2017 Dec 7;8(1):1988. doi: 10.1038/s41467-017-01573-6. Erratum in: Nat Commun. 2018 Jan 22;9(1):314.

17.

CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets.

Nowicka M, Krieg C, Weber LM, Hartmann FJ, Guglietta S, Becher B, Levesque MP, Robinson MD.

Version 2. F1000Res. 2017 May 26 [revised 2017 Jan 1];6:748. doi: 10.12688/f1000research.11622.2. eCollection 2017.

18.

Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer.

Qu Y, Olsen JR, Yuan X, Cheng PF, Levesque MP, Brokstad KA, Hoffman PS, Oyan AM, Zhang W, Kalland KH, Ke X.

Nat Chem Biol. 2018 Jan;14(1):94-101. doi: 10.1038/nchembio.2510. Epub 2017 Oct 30.

PMID:
29083417
19.

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.

Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A.

Oncotarget. 2017 May 25;8(41):69204-69218. doi: 10.18632/oncotarget.18213. eCollection 2017 Sep 19.

20.

NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis.

Singer J, Ruscheweyh HJ, Hofmann AL, Thurnherr T, Singer F, Toussaint NC, Ng CKY, Piscuoglio S, Beisel C, Christofori G, Dummer R, Hall MN, Krek W, Levesque MP, Manz MG, Moch H, Papassotiropoulos A, Stekhoven DJ, Wild P, Wüst T, Rinn B, Beerenwinkel N.

Bioinformatics. 2018 Jan 1;34(1):107-108. doi: 10.1093/bioinformatics/btx540.

21.

miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS.

Neu J, Dziunycz PJ, Dzung A, Lefort K, Falke M, Denzler R, Freiberger SN, Iotzova-Weiss G, Kuzmanov A, Levesque MP, Dotto GP, Hofbauer GFL.

PLoS One. 2017 Sep 20;12(9):e0185028. doi: 10.1371/journal.pone.0185028. eCollection 2017.

22.

MEK inhibition and immune responses in advanced melanoma.

Dummer R, Ramelyte E, Schindler S, Thürigen O, Levesque MP, Koelblinger P.

Oncoimmunology. 2017 Aug 10;6(8):e1335843. doi: 10.1080/2162402X.2017.1335843. eCollection 2017. Review.

23.

HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.

Ishida Y, Otsuka A, Tanaka H, Levesque MP, Dummer R, Kabashima K.

J Invest Dermatol. 2017 Nov;137(11):2443-2444. doi: 10.1016/j.jid.2017.06.023. Epub 2017 Jul 21. No abstract available.

PMID:
28736235
24.

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.

Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, Chen S, Boskovic ZV, Javaid S, Huang C, Wu X, Tseng YY, Roider EM, Gao D, Cleary JM, Wolpin BM, Mesirov JP, Haber DA, Engelman JA, Boehm JS, Kotz JD, Hon CS, Chen Y, Hahn WC, Levesque MP, Doench JG, Berens ME, Shamji AF, Clemons PA, Stockwell BR, Schreiber SL.

Nature. 2017 Jul 27;547(7664):453-457. doi: 10.1038/nature23007. Epub 2017 Jul 5.

25.

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.

Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C.

EMBO Mol Med. 2017 Aug;9(8):1011-1029. doi: 10.15252/emmm.201607156.

26.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.

Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R.

Melanoma Res. 2017 Aug;27(4):358-368. doi: 10.1097/CMR.0000000000000359.

27.

Sox2 is dispensable for primary melanoma and metastasis formation.

Schaefer SM, Segalada C, Cheng PF, Bonalli M, Parfejevs V, Levesque MP, Dummer R, Nicolis SK, Sommer L.

Oncogene. 2017 Aug;36(31):4516-4524. doi: 10.1038/onc.2017.55. Epub 2017 Apr 3.

28.

Metastatic melanoma moves on: translational science in the era of personalized medicine.

Levesque MP, Cheng PF, Raaijmakers MI, Saltari A, Dummer R.

Cancer Metastasis Rev. 2017 Mar;36(1):7-21. doi: 10.1007/s10555-017-9658-0. Review.

PMID:
28321632
29.

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?

Haueis SA, Kränzlin P, Mangana J, Cheng PF, Urosevic-Maiwald M, Braun RP, Levesque MP, Dummer R, Goldinger SM.

Melanoma Res. 2017 Jun;27(3):231-237. doi: 10.1097/CMR.0000000000000338.

30.

Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration.

Farsam V, Basu A, Gatzka M, Treiber N, Schneider LA, Mulaw MA, Lucas T, Kochanek S, Dummer R, Levesque MP, Wlaschek M, Scharffetter-Kochanek K.

Oncotarget. 2016 Dec 13;7(50):83554-83569. doi: 10.18632/oncotarget.13446.

31.

Field spectrometer measurement errors in presence of partially polarized light; evaluation of ground truth measurement accuracy.

Lévesque MP, Dissanska M.

Opt Express. 2016 Nov 28;24(24):27199-27211. doi: 10.1364/OE.24.027199.

PMID:
27906294
32.

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.

Raaijmakers MI, Widmer DS, Narechania A, Eichhoff O, Freiberger SN, Wenzina J, Cheng PF, Mihic-Probst D, Desalle R, Dummer R, Levesque MP.

Oncotarget. 2016 Nov 22;7(47):77163-77174. doi: 10.18632/oncotarget.12848.

33.

An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.

Thurneysen S, Cheng PF, Nagel HW, Kunz M, Jaberg-Bentele N, Nägeli M, Ziegler M, Guenova E, Goldinger SM, Mangana J, Levesque MP, Dummer R.

Br J Dermatol. 2016 Nov;175(5):966-978. doi: 10.1111/bjd.14727. Epub 2016 Sep 19.

34.

Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages.

Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque MP, Mangana J, Kerl K, Gebhardt C, Fujii H, Nakashima C, Nonomura Y, Kabashima K, Dummer R, Contassot E, French LE.

Sci Rep. 2016 Jul 18;6:29914. doi: 10.1038/srep29914.

35.

A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis.

Claps G, Cheli Y, Zhang T, Scortegagna M, Lau E, Kim H, Qi J, Li JL, James B, Dzung A, Levesque MP, Dummer R, Hayward NK, Bosenberg M, Brown KM, Ronai ZA.

Cell Rep. 2016 May 31;15(9):1884-92. doi: 10.1016/j.celrep.2016.04.072. Epub 2016 May 19.

36.

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C.

Cancer Cell. 2016 Mar 14;29(3):270-284. doi: 10.1016/j.ccell.2016.02.003.

37.

Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.

Paulitschke V, Eichhoff O, Cheng PF, Levesque MP, Höller C.

Curr Opin Oncol. 2016 Mar;28(2):172-9. doi: 10.1097/CCO.0000000000000261. Review.

PMID:
26742019
38.

Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.

Rozati S, Cheng PF, Widmer DS, Fujii K, Levesque MP, Dummer R.

Clin Cancer Res. 2016 Apr 15;22(8):2020-31. doi: 10.1158/1078-0432.CCR-15-1435. Epub 2015 Dec 9.

39.

Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations.

Rolfs F, Huber M, Kuehne A, Kramer S, Haertel E, Muzumdar S, Wagner J, Tanner Y, Böhm F, Smola S, Zamboni N, Levesque MP, Dummer R, Beer HD, Hohl D, Werner S, Schäfer M.

Cancer Res. 2015 Nov 15;75(22):4817-29. doi: 10.1158/0008-5472.CAN-15-0614. Epub 2015 Nov 3.

40.

Perturbing resistance: a network perspective.

Levesque MP, Dummer R, Beerenwinkel N.

Pigment Cell Melanoma Res. 2016 Jan;29(1):5-7. doi: 10.1111/pcmr.12431. No abstract available.

PMID:
26471867
41.

Data mining The Cancer Genome Atlas in the era of precision cancer medicine.

Cheng PF, Dummer R, Levesque MP.

Swiss Med Wkly. 2015 Sep 16;145:w14183. doi: 10.4414/smw.2015.14183. eCollection 2015. Review.

42.

Naevus spilus-type congenital melanocytic naevus associated with a novel NRAS codon 61 mutation.

Krengel S, Widmer DS, Kerl K, Levesque MP, Schiestl C, Weibel L.

Br J Dermatol. 2016 Mar;174(3):642-4. doi: 10.1111/bjd.14105. Epub 2015 Nov 21. No abstract available.

PMID:
26302237
43.

A Floor-Plate Extracellular Protein-Protein Interaction Screen Identifies Draxin as a Secreted Netrin-1 Antagonist.

Gao X, Metzger U, Panza P, Mahalwar P, Alsheimer S, Geiger H, Maischein HM, Levesque MP, Templin M, Söllner C.

Cell Rep. 2015 Jul 28;12(4):694-708. doi: 10.1016/j.celrep.2015.06.047. Epub 2015 Jul 16.

44.

Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2.

Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF.

Mol Cancer Ther. 2015 Sep;14(9):2132-42. doi: 10.1158/1535-7163.MCT-15-0023-T. Epub 2015 Jun 26.

45.

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.

Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA.

Cell Rep. 2015 Jun 9;11(9):1458-73. doi: 10.1016/j.celrep.2015.04.049. Epub 2015 May 28.

46.

Melanoma's next top model, it is in the air.

Widmer DS, Eichhoff OM, Dummer R, Levesque MP.

Exp Dermatol. 2015 Sep;24(9):659-60. doi: 10.1111/exd.12757. Epub 2015 Jun 4. No abstract available.

PMID:
25977109
47.

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.

Cheng PF, Shakhova O, Widmer DS, Eichhoff OM, Zingg D, Frommel SC, Belloni B, Raaijmakers MI, Goldinger SM, Santoro R, Hemmi S, Sommer L, Dummer R, Levesque MP.

Genome Biol. 2015 Feb 22;16:42. doi: 10.1186/s13059-015-0594-4.

48.

Hedgehog signaling in basal cell carcinoma.

Otsuka A, Levesque MP, Dummer R, Kabashima K.

J Dermatol Sci. 2015 May;78(2):95-100. doi: 10.1016/j.jdermsci.2015.02.007. Epub 2015 Feb 23. Review.

PMID:
25766766
49.

A new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies.

Raaijmakers MI, Widmer DS, Maudrich M, Koch T, Langer A, Flace A, Schnyder C, Dummer R, Levesque MP.

Exp Dermatol. 2015 May;24(5):377-80. doi: 10.1111/exd.12683.

PMID:
25739758
50.

Curing advanced melanoma by 2025.

Dummer R, Goldinger SM, Paulitschke V, Levesque MP.

Curr Opin Oncol. 2015 Mar;27(2):125-7. doi: 10.1097/CCO.0000000000000168. Review.

Supplemental Content

Loading ...
Support Center